3 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 3, Active not recruiting 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
Follow Lymphoma, Primary Effusion: new trials by email Literature Review of Lymphoma, Primary Effusion trials Research Report on Lymphoma, Primary Effusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease Daratumumab SC - Lymphoma, Primary Effusion | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-07-10 | 2026-10-16 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 HST-NEETs, Bone Marrow Transplant - HIV Associated Lymphoma | Phase 2 | Completed | Catherine Bollard | 12 | 2021-10-25 | 2026-06-29 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Lenalidomide, Rituximab, Prednisone - Primary Effusion Lymphoma, B-Cell Neoplasm | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2017-07-03 | 2026-10-20 |
| Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas Pomalidomide, Rituximab, Prednisone - Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2014-08-15 | 2018-08-31 | |
| Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 107 | 2010-10-06 | 2023-11-21 |
| Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma carmustine, cyclophosphamide, etoposide - Lymphoma | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 473 | 2005-08-24 | 2020-07-14 |
| Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas Pegylated Liposomal Doxorubicin (Doxil) and Rituximab - Non-Hodgkin's Lymphoma, Burkitt Lymphoma | Phase 2 | Terminated | University of Southern California | 15 | 2005-04-01 | 2014-05-22 |
Lymphoma, Non-Hodgkin (4) · Lymphoma, B-Cell (3) · Burkitt Lymphoma (2) · Lymphoma (2) · Lymphoma, Large B-Cell, Diffuse (2) · Plasmablastic Lymphoma (2) · HIV Infections (1) · Hodgkin Disease (1) · Lymphoma, AIDS-Related (1) · Lymphoma, Follicular (1) · Lymphomatoid Granulomatosis (1) · Multi-centric Castleman's Disease (1) · Sarcoma, Kaposi (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma (7) · Lymphoma, B-Cell (6) · Lymphoma, Non-Hodgkin (5) · Infections (4) · Virus Diseases (4) · DNA Virus Infections (3) · Herpesviridae Infections (3) · Epstein-Barr Virus Infections (2)
Cyclophosphamide (4) · Etoposide (4) · Rituximab (4) · Doxorubicin (3) · Prednisone (3) · Vincristine (3) · liposomal doxorubicin (2) · Bone Marrow Transplantation (1) · Bronchoscopy (1) · CT-P10 (1) · Carmustine (1) · Cytarabine (1) · Disulfides (1) · Echocardiography (1) · Electrocardiography (1)
National Cancer Institute (NCI) (5) · Catherine Bollard (1) · Estrella Immunopharma, Inc. (1) · Masonic Cancer Center, University of Minnesota (1) · University of Southern California (1)
United States (8)
Anil Tulpule, MD (1) · Juan C Ramos (1) · Pei Wang, PhD (1) · Ramya Ramaswami, MBBS, MPH (1) · Robert Yarchoan, M.D. (1) · Stephen M Ansell (1) · Steve Devine, MD, MS (1) · Thomas S Uldrick, M.D. (1) · Veronika Bachanova, MD (1)
U10HL069294 (1), UM1CA121947 (1), UM1CA186686 (1), UM1CA186709 (1)